You are here

  • Home
  • Archive
  • Volume 9, Issue 9
  • Comparing docosahexaenoic acid (DHA) concomitant with neoadjuvant chemotherapy versus neoadjuvant chemotherapy alone in the treatment of breast cancer (DHA WIN): protocol of a double-blind, phase II, randomised controlled trial

Citation Tools

Article menu

Download PDFPDF

XML
Oncology
Protocol
Comparing docosahexaenoic acid (DHA) concomitant with neoadjuvant chemotherapy versus neoadjuvant chemotherapy alone in the treatment of breast cancer (DHA WIN): protocol of a double-blind, phase II, randomised controlled trial

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Newell M, Mackey JR, Bigras G, et al
Comparing docosahexaenoic acid (DHA) concomitant with neoadjuvant chemotherapy versus neoadjuvant chemotherapy alone in the treatment of breast cancer (DHA WIN): protocol of a double-blind, phase II, randomised controlled trial
BMJ Open 2019;9:e030502. doi: 10.1136/bmjopen-2019-030502